SEC Form 4 · accession 0001933414-26-000120
Mineralys Therapeutics, Inc. · MLYS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James J. Ferguson III
Officer — Chief Medical Officer
Period of report
Aug 10, 2026
Accepted (ET)
Aug 12, 2026 · 7:33 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001933414
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 10, 2026 | A | 102,400 | $0.00 | A | 102,400 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF2 | $27.38 | Aug 10, 2026 | A | 135,000 | A | — | Aug 10, 2036 | Common Stock | 135,000 | 135,000 | D |
Explanation of responses
- F1Restricted Stock Units (RSUs) are granted to the reporting person for no additional cash consideration, each of which represents a contingent right to receive one share of common stock upon vesting. The RSUs vest in annual installments over a period of four years, with 1/4th of the total shares underlying the RSU vesting on each one-year anniversary of the date of grant.
- F2The stock option vests as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.